These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34267780)

  • 1. A Robust Prognostic Gene Signature Based on eRNAs-Driven Genes in Prostate Cancer.
    Fan S; Wang Z; Zhao L; Zhao C; Yuan D; Wang J
    Front Genet; 2021; 12():676845. PubMed ID: 34267780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.
    Wu P; Shi J; Wang Z; Sun W; Zhang H
    Cancer Cell Int; 2022 Oct; 22(1):307. PubMed ID: 36217201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.
    Cai S; Hu X; Chen R; Zhang Y
    Front Genet; 2021; 12():657051. PubMed ID: 34178028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer.
    Xiong Z; Ge Y; Xiao J; Wang Y; Li L; Ma S; Lan L; Liu B; Qin B; Luan Y; Yang C; Ye Z; Wang Z
    Exp Biol Med (Maywood); 2023 Jan; 248(1):1-13. PubMed ID: 36408742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
    Cheng L; Han T; Chen B; Nie K; Peng W
    BMC Cancer; 2021 Jul; 21(1):794. PubMed ID: 34238250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
    Wu X; Zhao X; Zhou C; Wei N; Xu Z; Zhang X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):188. PubMed ID: 38602568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A four-enhancer RNA-based prognostic signature for thyroid cancer.
    Liang Y; Zhang Q; Xin T; Zhang DL
    Exp Cell Res; 2022 Mar; 412(2):113023. PubMed ID: 35033555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An enhancer RNA-based risk model for prediction of bladder cancer prognosis.
    Xu Z; Xu C; Wang Q; Ma S; Li Y; Liu S; Peng S; Tan J; Zhao X; Han D; Zhang K; Yang L
    Front Med (Lausanne); 2022; 9():979542. PubMed ID: 36186809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive transcriptomic analysis of immune-related eRNAs associated with prognosis and immune microenvironment in melanoma.
    Gan Y; Yang Y; Wu Y; Li T; Liu L; Liang F; Qi J; Liang P; Pan D
    Front Surg; 2022; 9():917061. PubMed ID: 36338651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes.
    Tian W; Yan G; Chen K; Han X; Zhang W; Sun L; Zhang Q; Zhang Y; Li Y; Liu M; Zhang Q
    Front Oncol; 2022; 12():714338. PubMed ID: 35299740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutator-derived prognostic eRNA signature provides insight into the pathogenesis of breast cancer.
    Wang R; Gou Y; Tang M; Wang K; He H; Yang J; Yang Y; Jing Y; Tang Q
    Exp Cell Res; 2023 Oct; 431(1):113754. PubMed ID: 37611728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and validation of a novel cuproptosis-related long noncoding RNA signature for predicting the outcome of prostate cancer.
    Jiang S; Li Z; Dou R; Lin Z; Zhang J; Zhang W; Chen Z; Shen X; Ji J; Qu M; Wang Y; Li M; Gao X
    Front Genet; 2022; 13():976850. PubMed ID: 36561322
    [No Abstract]   [Full Text] [Related]  

  • 13. EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer.
    Liu GX; Tan YZ; He GC; Zhang QL; Liu P
    Medicine (Baltimore); 2021 Oct; 100(41):e27535. PubMed ID: 34731149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
    Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
    Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 as Novel Prognostic Biomarkers in Uveal Melanoma.
    Zhao S; Jiang H; Liu J; Li DY; Li B; Long QR; Zheng L; Gu H
    Dis Markers; 2022; 2022():5994800. PubMed ID: 35251374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
    Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
    Front Genet; 2023; 14():1096783. PubMed ID: 36911392
    [No Abstract]   [Full Text] [Related]  

  • 17. eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.
    Jiang Z; Long J; Deng K; Zheng Y; Chen M
    Front Mol Biosci; 2022; 9():877117. PubMed ID: 35586193
    [No Abstract]   [Full Text] [Related]  

  • 18. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.
    Bu X; Liu S; Zhang Z; Wu J; Pan S; Hu Y
    Clin Transl Oncol; 2024 Apr; 26(4):891-904. PubMed ID: 37697139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.